SciBase Reports Significant Growth in Q4 2025 Amidst Challenges in Market Dynamics

SciBase Interim Report Overview

Net Sales Performance
During the fourth quarter of 2025, SciBase reported net sales amounting to TSEK 12,475, which marks a substantial increase of 45% compared to the same period in the previous year. When adjusted for currency fluctuations, the sales growth was even more impressive at 57%. This growth trajectory is indicative of the rising demand for SciBase's innovative products, particularly in the dermatology sector, where they focus on early detection of skin conditions.

Financial Metrics
Despite the rise in sales, the company experienced a net loss after tax of TSEK 25,300, which is a slight increase from TSEK 21,677 in the preceding year. The loss per share was SEK 0.06, improving from SEK 0.10 in Q4 2024. However, cash flow from current operations took a downturn, recorded at a negative TSEK 20,824, which was worse than the previous year's negative TSEK 12,548. The gross margin also saw a decline to 63% from 68.5%.

Sales Growth in Electrode Volume
A notable bright spot for the company was the remarkable 67% increase in electrode sales volume, with a total of 28,634 units sold compared to just 17,132 units in Q4 2024. The repeat sales to existing customers also demonstrated strength, rising by 48%, which underscores the company's customer retention and product efficacy.

Full Year Financial Performance

On a full-year basis, net sales reached TSEK 40,461, a 36% increase from TSEK 29,705 in 2024, with currency-adjusted growth at approximately 43%. The total loss after tax for the year was TSEK 87,063, up from TSEK 65,579 in the previous year. This resulted in a loss per share of SEK 0.24 compared to SEK 0.37 for 2024.

Operational Challenges
The gross margin stood at 67% for the year, down from 71% in 2024, reflecting challenges posed by rising operational costs and currency impacts. For the twelve-month period, the total electrode sales volume increased by 38%, resulting in 86,180 units sold, with repeat sales increasing by 35%.

Key Developments and Collaborations

Several important events marked the quarter, including an increase in overall sales, particularly in the skin cancer segment, where sales in the US surged by 84% and by 13% in Germany. The company's collaboration with Castle Biosciences expanded, signaling a strategic move to enhance clinical study efforts. The decision to execute a rights issue of SEK ~83 million was made by SciBase's Board, along with a significant loan agreement with Castle Biosciences.

Patent Portfolio Expansion
During this quarter, SciBase also announced the expansion of its patent portfolio, further strengthening its competitive position in the dermatology field. A nomination committee was formed for the upcoming Annual General Meeting, setting the stage for the company’s future governance and strategic direction.

Recent Developments Post-Quarter

After the close of the quarter, SciBase shared encouraging news regarding their rights issue, revealing a subscription rate of 96.4%, which is expected to bolster the firm’s operational cash flow. A new study showcasing the predictive ability of Nevisense in diagnosing atopic dermatitis in newborns was announced, highlighting the innovative potential of SciBase’s technologies. Additionally, Nevisense has been incorporated into the US NCCN guidelines for melanoma detection, affirming its clinical significance and utility.

FDA Approval
Furthermore, SciBase received FDA approval for expanded labeling of Nevisense in the US market, thereby enhancing visibility and accessibility in a critical healthcare sector. Overall, while the company faces several operational and financial challenges, including a negative cash flow, the positive growth trends in sales and proactive measures taken by management reflect SciBase’s commitment to stabilizing and advancing its market position in dermatology.

Conclusion

In summary, the 2025 interim report from SciBase underscores both the challenges and the opportunities the company faces as it navigates the complex landscape of the healthcare market. With steady growth in revenue and strategic collaborations, SciBase is poised for future success, provided it continues to innovate and adapt in the evolving market environment.